Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial
Most Cited Paper
in Estrogen and related hormone effects
18 Months Post-Publication
Class of 2026
“Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
enobosarm · selective androgen receptor modulator · androgen receptor · estrogen receptor-positive breast cancer · HER2-negative breast cancer · AR-positive disease · ER-positive advanced breast cancer · androgen receptor as tumour suppressor · clinical benefit rate · menopause · advanced breast cancer · AR activation · drug-induced liver injury · hypercalcaemia · endocrine therapy · Bone metastases · phase 2 trial · selective androgen receptor modulator
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026. https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026. Accessed 2026-07-31. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459